Fuchs, Eberhard

[["dc.bibliographiccitation.firstpage","31"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Cell and Tissue Research"],["dc.bibliographiccitation.lastpage","41"],["dc.bibliographiccitation.volume","357"],["dc.contributor.author","Fluegge, Gabriele"],["dc.contributor.author","Araya-Callis, Carolina"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Stadelmann-Nessler, Christine"],["dc.contributor.author","Fuchs, Eberhard"],["dc.date.accessioned","2018-11-07T09:38:14Z"],["dc.date.available","2018-11-07T09:38:14Z"],["dc.date.issued","2014"],["dc.description.abstract","The protein NDRG2 (N-myc downregulated gene 2) is expressed in astrocytes. We show here that NDRG2 is located in the cytosol of protoplasmic and fibrous astrocytes throughout the mammalian brain, including Bergmann glia as observed in mouse, rat, tree shrew, marmoset and human. NDRG2 immunoreactivity is detectable in the astrocytic cell bodies and excrescencies including fine distal processes. Glutamatergic and GABAergic nerve terminals are associated with NDRG2 immunopositive astrocytic processes. Muller glia in the retina displays no NDRG2 immunoreactivity. NDRG2 positive astrocytes are more abundant and more evenly distributed in the brain than GFAP (glial fibrillary acidic protein) immunoreactive cells. Some regions with very little GFAP such as the caudate nucleus show pronounced NDRG2 immunoreactivity. In white matter areas, NDRG2 is less strong than GFAP labeling. Most NDRG2 positive somata are immunoreactive for S100 but not all S100 cells express NDRG2. NDRG2 positive astrocytes do not express nestin and NG2 (chondroitin sulfate proteoglycan 4). The localization of NDRG2 overlaps only partially with that of aquaporin 4, the membrane-bound water channel that is concentrated in the astrocytic endfeet. Reactive astrocytes at a cortical lesion display very little NDRG2, which indicates that expression of the protein is reduced in reactive astrocytes. In conclusion, our data show that NDRG2 is a specific marker for a large population of mature, non-reactive brain astrocytes. Visualization of NDRG2 immunoreactive structures may serve as a reliable tool for quantitative studies on numbers of astrocytes in distinct brain regions and for high-resolution microscopy studies on distal astrocytic processes."],["dc.identifier.doi","10.1007/s00441-014-1837-5"],["dc.identifier.isi","000338759900003"],["dc.identifier.pmid","24816982"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10233"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33027"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-0878"],["dc.relation.issn","0302-766X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","NDRG2 as a marker protein for brain astrocytes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0149776"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Eesmaa, Ave"],["dc.contributor.author","Lindholm, Paeivi"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Koenig, Jessica"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Krieglstein, Kerstin"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Saarma, Mart"],["dc.contributor.author","Fuchs, Eberhard"],["dc.date.accessioned","2018-11-07T10:18:05Z"],["dc.date.available","2018-11-07T10:18:05Z"],["dc.date.issued","2016"],["dc.description.abstract","Cerebral dopamine neurotrophic factor (CDNF) belongs to a newly discovered family of evolutionarily conserved neurotrophic factors. We demonstrate for the first time a therapeutic effect of CDNF in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of Parkinson's disease in marmoset monkeys. Furthermore, we tested the impact of high chronic doses of human recombinant CDNF on unlesionedmonkeys and analyzed the amino acid sequence ofmarmoset CDNF. The severity of 6-OHDA lesions and treatment effects weremonitored in vivo using 123I-FP-CIT (DaTSCAN) SPECT. Quantitative analysis of 123I-FP-CIT SPECT showed a significant increase of dopamine transporter binding activity in lesioned animals treated with CDNF. Glial cell line-derived neurotrophic factor (GDNF), a well-characterized and potent neurotrophic factor for dopamine neurons, served as a control in a parallel comparison with CDNF. By contrast with CDNF, only single animals responded to the treatment with GDNF, but no statistical difference was observed in the GDNF group. However, increased numbers of tyrosine hydroxylase immunoreactive neurons, observed within the lesioned caudate nucleus of GDNF-treated animals, indicate a strong bioactive potential of GDNF."],["dc.identifier.doi","10.1371/journal.pone.0149776"],["dc.identifier.isi","000371276100150"],["dc.identifier.pmid","26901822"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12929"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41359"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","195"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neuroscience Methods"],["dc.bibliographiccitation.lastpage","201"],["dc.bibliographiccitation.volume","210"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Czeh, Boldizsar"],["dc.contributor.author","Koenig, Jessica"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Heckmann, Cornelia"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Fuchs, Eberhard"],["dc.date.accessioned","2018-11-07T09:05:41Z"],["dc.date.available","2018-11-07T09:05:41Z"],["dc.date.issued","2012"],["dc.description.abstract","Considerable progress has been made in small animal single photon emission computed tomography (SPECT) imaging in the field of Parkinson's disease. In preclinical research, there is an increasing demand for in vivo imaging techniques to apply to animal models. Here, we report the first protocol for dopamine transporter (DAT) SPECT in common marmosets using the radioligand I-123-N-omega-fluoropropyl-2 beta-carbomethoxy-3 beta-{4-iodophenyl}nortropane (I-123-FP-CIT). Serial SPECT images were obtained on an upgraded clinical scanner to determine the distribution kinetics of I-123-FP-CIT in the marmoset brain. After intravenous injection of approximately 60 MBq of the radiotracer I-123-FP-CIT, stable and specific striatal uptake was observed for at least 4 h. Analysis of plasma samples showed rapid disappearance of the radiotracer from blood plasma within a few minutes after application, with activity declining to 4.1% of the administered activity. Structural magnetic resonance imaging (MRI) at 400 mu m resolution provided the details of the underlying anatomy. In a marmoset model of Parkinson's disease, which was generated by unilateral injections of 6-hydroxydopamine (6-OHDA) into the nigro-striatal projection pathway, complete loss of striatal DAT binding in combination with behavioral deficits was observed. The presented study demonstrates that I-123-FP-CIT SPECT is a suitable tool to investigate DAT integrity in preclinical studies on common marmosets. (C) 2012 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.jneumeth.2012.07.009"],["dc.identifier.isi","000309376900009"],["dc.identifier.pmid","22827895"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11318"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25384"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0165-0270"],["dc.rights","CC BY-NC-ND 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/3.0"],["dc.title","Visualizing dopamine transporter integrity with iodine-123-FP-CIT SPECT in combination with high resolution MRI in the brain of the common marmoset monkey"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]